Tuesday, September 20, 2011 - Actos, the popular diabetes medication made by Takeda Pharmaceuticals, Inc., has been linked to bladder cancer with enough certainty for the FDA to issue two safety communications concerning Actos bladder cancer within a 12-month period. The first FDA Actos safety notice described an increased risk of developing bladder cancer after taking Actos for two years or more. On June 15, 2011 the FDA updated its Actos safety notice, stating that Actos users may increase their risk of bladder cancer by taking the drug for more than one year. Actos remains in widespread use in the United States, although sales have been suspended in France and Germany.
Actos is used to control blood sugar in adults with Type 2 diabetes. It has been linked to increased risk of bladder cancer in tests in both the US and Europe and is part of an ongoing 10-year study by Takeda Pharmaceuticals, Inc. The FDA Actos bladder cancer safety notices were precipitated by the results from an interim analysis of the Actos safety study by Takeda Pharmaceuticals, Inc.
The Onder Law Firm, a prominent national law firm with a long history of representing clients harmed by dangerous drugs and defective medical devices, is offering a free, no-obligation Actos bladder cancer claim review to families of persons whom have been diagnosed with bladder cancer after using Actos. All Actos bladder cancer lawsuits handled by The Onder Law Firm will be done on a contingency basis.
The Onder Law Firm welcomes Actos bladder cancer inquiries from law firms in regards to handling them or working as co-counsel.